Capstone Green Energy to Deliver Scalable 2MW Microturbine System for Government-Backed Power Station in Remote Oceania Community
LOS ANGELES--(BUSINESS WIRE)-- Capstone Green Energy Holdings, Inc. (the "Company' or 'Capstone') (PINK: CGEH) and Capstone Green Energy, LLC., announced that its Australian distributor, Optimal Group, has been selected as the EPC (engineering, procurement, and construction) contractor for a remote community power generation project in the Oceania region. The project will deploy two Capstone C1000S Signature Series microturbines in a scalable configuration to deliver an initial 2 megawatts (MW) of reliable, low-emission power to an isolated community. This system is designed for expansion, with the ability to scale up to 5MW of power.
These solutions, which are renewable fuel-ready, integrate seamlessly with other renewable energy systems as well.
Commissioning of the initial 2MW installation is targeted for November 2025. The power station will be located near a natural gas fuel conditioning plant for conversion into LPG that will serve the Asia Pacific region. The project will off-take a portion of the natural gas from this process for the Capstone microturbines. The power generated by this facility will be exported to the local grid, meeting the community's current energy demand of 2MW. As additional residents and businesses connect to the grid over the coming years, the station's capacity is expected to scale up to 5MW.
'Being able to serve the needs of remote, underserved communities is especially meaningful for us,' said Vince Canino, President and CEO of Capstone Green Energy. 'Our ability to operate on alternate fuels in such isolated locations reinforces Capstone's original design philosophy of providing compact and mobile power solutions – visionary thinking that was introduced by Capstone's founders, James Noe and Robin McKay, almost 40 years ago. Our long-standing company culture of daring greatly and iterating towards success is why Capstone's microturbines can provide a much lower carbon footprint on a sustainable basis compared to diesel generators, and we are able to do so while offering unmatched reliability and availability. Even in the most challenging environments, we are able to provide a very attractive total cost of electricity.'
Capstone's modular microturbine design allows the system to easily scale with growing demand, ideal for evolving community needs. With a single-shaft design as the only moving part, plus air bearings that eliminate the need for lubricating oils and coolants, Capstone microturbines require minimal maintenance. This not only creates some of the highest availability factors in the industry, but it also leads to significant cost savings—an essential benefit for any project in remote locations.
This project will also transition the region away from reliance on diesel for power generation. By utilizing refined natural gas instead of diesel, the project will reduce NOx, CO2, and VOC emissions. It will also eliminate particulate matter (PM2.5) emissions all together. Additional benefits that contributed to the selection of Capstone's technology include its quieter operation. Because our microturbines run on a cushion of air, noise is significantly less than that of reciprocating engines which run at substantially higher decibel levels.
'This is yet another project that showcases our commitment to transitioning businesses and communities away from the pollution and messiness of diesel generation. This power station will provide a reliable source of electricity to the local community and significantly reduce greenhouse gas emissions. Energy security will also be enhanced via the use of locally produced gaseous fuel,' said Craig Dugan, CEO of Optimal Group. 'Optimal's territory includes some of the most remote and challenging locations globally. Leveraging Capstone's technological flexibility allows us to deliver intelligently clean solutions at a lower total cost of ownership, with high availability and reliability. These solutions, which are renewable fuel-ready, integrate seamlessly with other renewable energy systems as well. We not only can make an impact today, but we have also designed in the ability to be future proof.'
About Capstone Green Energy
For almost four decades, Capstone Green Energy has been at the forefront of clean technology using microturbines and revolutionizing how businesses manage their energy supply on a sustainable basis. In partnership with our worldwide team of dedicated distributors, we have shipped over 10,000 units to 83 countries, lowering our clients' carbon footprint with highly efficient on-site energy systems and microgrid solutions.
Today, our commitment to a cleaner future is unwavering. We offer customers a range of microturbine products ranging from 65kW to multiple MW's for the commercial, industrial, and utility-scale spaces uniquely tailored to their specific needs. Capstone's solutions portfolio not only showcases our core clean technology microturbines but also includes flexible Energy-as-a-Service (EaaS) offerings, including build, own, and operate models, as well as rental services.
Capstone's fast, turnkey power rental solutions are intended to address customers with limited capital or short-term needs; for more information, contact rentals@CGRNenergy.com.
In our pursuit of cutting-edge solutions, we've forged strategic partnerships to extend our impact. Through these collaborations, we proudly offer solutions that utilize renewable gas products and heat recovery solutions. These solutions greatly enhance the sustainability and efficiency of our client's operations while contributing to a cleaner and more responsible sustainable energy landscape.
For more information about the Company, please visit www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.
Cautionary Notes
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The Company has tried to identify these forward-looking statements by using words such as 'expect,' 'anticipate,' 'believe,' 'could,' 'should,' 'estimate,' 'intend,' 'may,' 'will,' 'plan,' 'goal' and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the Company's liquidity position and ability to access capital; the Company's ability to continue as a going concern; the Company's ability to successfully remediate the material weaknesses in internal control over financial reporting; the Company's ability to realize the anticipated benefits of its financial restructuring; the Company's ability to comply with the restrictions imposed by covenants contained in the exit financing and the new subsidiary limited liability company agreement; the uncertainty associated with the imposition of tariffs and trade barriers and changes in trade policies; employee attrition and the Company's ability to retain senior management and other key personnel; the Company's ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the impact of litigation and regulatory proceedings; inquiries from the SEC; the potential material adverse effect on the price of the Company's common stock and stockholder lawsuits. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Annual Report on Form 10-K. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
8 hours ago
- CNBC
How activist Barington Capital can collaborate with Victoria's Secret to improve shareholder value
Business: Victoria's Secret & Co. is a specialty retailer of women's apparel and beauty products marketed under the Victoria's Secret, Pink and Adore Me brand names. Victoria's Secret brand offers intimate apparel, casual sleepwear, swim, lounge and sport, as well as fragrances and body care. Pink is a lifestyle brand for young women providing variety of collections and heritage pieces, including intimate apparel, loungewear, activewear, accessories, beauty and more. Adore Me is a direct-to-consumer lingerie and apparel brand that is focused on serving women of all sizes and budgets. Stock Market Value: $1.5B ($18.83 per share) Ownership: > 1% Average Cost: n/a Activist Commentary: Barington was founded in 1992 by James A. Mitarotonda as a boutique, full-service investment bank to serve the needs of emerging growth and smaller capitalization companies. The success of the firm and its investments led to the wind-down of the investment bank and the launch of an activist hedge fund in 2000. In its history, Barington has taken material action at 38 other companies and has averaged a 38.18% return on these investments versus 14.74% for the Russell 2000 over the same period. Barington is advocating for Victoria's Secret to (i) replace at least a majority, if not all, of the board with directors who have proven experience in brand revitalization, operational execution, international expansion and shareholder value creation (six of the nine current directors have been on the board since its public listing); (ii) have the reconstituted board consider whether CEO Hillary Super has the experience and strategic clarity necessary to engineer a turnaround; (iii) dedicate additional focus to its core brand; (iv) accelerate growth in digital and international markets; and (v) streamline the operating model eliminating underperforming and distracting initiatives. Victoria's Secret & Co. ("VSCO") is a specialty retailer of lingerie, clothing and beauty products through its flagship Victoria's Secret brand, Pink and Adore Me. The company began trading on the New York Stock Exchange in summer 2021 following a spin-off from L Brands (which is now Bath & Body Works). The company's nearly four-year stint in the public markets has been marked by difficulties. Trading at an all-time high of roughly $76 per share not long after its debut, shares have fallen more than 75% to around $18 per share. Investor BBRC International PTE Limited converted from a 13G to a 13D in February 2024 and built its position to nearly 13% as VSCO shares continued to tumble. Earlier this month, BBRC sent a letter to Victoria's Secret Chair Donna James in which it lambasted the board for its history of value destruction. BBRC's letter is short on support and detail and long on allegation, negativity and second guessing with the benefit of hindsight. The only suggestion the investor makes states the obvious: "constructing a confidence-inspiring Board and generating positive financial returns to drive value creation." Thankfully for Victoria's Secret and its shareholders, a more constructive and experienced activist showed up: Barington Capital. On June 16, Barington sent a letter to the board of VSCO notifying the company of its more than 1% position. Then in its very next paragraph, Barington uses words like "constructively," "collaboratively" and "helpful." The firm does not just claim to have industry experience, but cites its engagement with L Brands, the former parent company of VSCO, which led to an increase in the stock price by 221.5% during its tenure as an advisor to the board of directors. Like BBRC, Barington criticizes the company's dismal underperformance, trailing its peers by 47.4 percentage points since its IPO. But while BBRC was content with just being critical, Barington specifically identifies several reasons for the underperformance such as declining revenue, shrinking gross margins, growing inventory, high senior management turnover, a lack of marketing and merchandising focus and an apparent failure to articulate or execute a compelling brand vision. Had Barington just left it there, the firm would have been more helpful than BBRC. However, as a responsible and experienced shareholder activist, Barington takes it to the next integral step – suggestions on a path forward. Specifically, Barington recommended that Victoria's Secret: (i) replace at least a majority, if not all, of the board with directors who have proven experience in brand revitalization, operational execution, international expansion and shareholder value creation (six of the nine current directors have been on the board since its public listing); (ii) have the reconstituted board consider whether CEO Hillary Super has the experience and strategic clarity necessary to engineer a turnaround; (iii) dedicate additional focus to its core brand; (iv) accelerate growth in digital and international markets; and (v) streamline the operating model eliminating underperforming and distracting initiatives. Barington is no stranger to VSCO. In fact, the firm was a vocal proponent of the spin in a previous 2019 campaign at L Brands. At the time, Barington recommended that the company take swift action to improve the performance of VSCO by correcting merchandising mistakes and launching a strategic review to unlock value through a separation of VSCO from Bath & Body Works. The two parties eventually entered into an agreement pursuant to which L Brands appointed Barington as a special advisor to the company, and Barington agreed to withdraw its proposed nominees to the board. Ultimately, VSCO was spun and Barington generated a return of over 221.5% during its tenure as an advisor to the board. Barington may not be a household name in the investor world like many activists, but it has as much experience as any activist today. The firm's activism dates back to 2000, and much of it was focused on the retail sector, targeting companies like Hanesbrands, Chico's FAS and Dillard's. Of its 46 campaigns, 19 have been at consumer discretionary companies, at which the firm has had an average return of 13.86% versus 8.56% for the Russell 2000 over the same period. Barington does not like spending what it takes to win a proxy fight, preferring to gain representation through settlements. Its recent proxy fight and loss at Matthews International was evidence of this, but also showed that Barington is still willing to take a proxy fight to the distance. Barington is not likely to go through that again so soon, but given its experience in this industry and at Victoria's Secret (two of the current directors, including Chair Donna James, were directors when Barington successfully collaboratively engaged in 2019), we would expect that the firm would have a good opportunity to work constructively and amicably with the board to create shareholder value.
Business Wire
8 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Yahoo
8 hours ago
- Yahoo
Hong Kong Airlines Celebrates Inaugural Flight to Sydney
Offering Travellers More Direct Flight Options to Australia HONG KONG, June 21, 2025 /PRNewswire/ -- Hong Kong Airlines' inaugural flight between Hong Kong and Sydney, Australia, departed yesterday, making it the second local airline to operate this route and providing greater travel options for business, leisure, and transit passengers. To mark this new milestone in its network expansion, Hong Kong Airlines held celebratory events at both Hong Kong International Airport (HKIA) and Sydney Airport (SYD). Prior to departure, a launch ceremony was held at the boarding gate of the HKIA. The event was attended by distinguished guests, including Mr Jeff Sun, President of Hong Kong Airlines; Mr Ian McGraw from the Australian Consulate-General in Hong Kong; Ms Carmen Tam and Ms Vivien Yuen from Tourism Australia; Ms Jennifer Tung from Destination New South Wales; and Mr Ricky Chong from Airport Authority Hong Kong. The guests interacted with passengers and presented them with bespoke souvenirs to commemorate the historic occasion. During the event, Hong Kong Airlines President Mr Jeff Sun stated: "As a full-service local carrier, the launch of our Sydney service marks a significant step in our transformation to an international airline. Sydney is not only a popular destination for leisure and business travel but also one of Australia's most vital economic hubs. The expansion of the bilateral traffic rights agreement allows us to offer more choice to travellers in both cities, strengthening the connection between them." He added, "While Hong Kong Airlines may be a younger brand in the mature Australian market, we are endeavouring in our commitment to providing quality service. We operate this route with our Airbus A330 aircraft, featuring comfortable business and economy class cabins, and strive to deliver a passenger-centric in-flight experience through attentive service and fine dining for our long-haul customers." Sydney Airport CEO Mr Scott Charlton said: "We're proud to welcome Hong Kong Airlines to Sydney as our 52nd airline partner with its strong reputation for service excellence, efficiency and value. This inaugural service comes on the back of the first expansion in bilateral air traffic rights between Australia and Hong Kong in 19 years and we thank the Albanese Federal Government for its role in enabling this important agreement, which reflects the strength of our longstanding cultural and economic ties." NSW Minister for Jobs and Tourism Steve Kamper, said: "Hong Kong is a priority international market for NSW, with incoming travellers contributing substantially to the NSW visitor economy. The Minns Labor Government has made it very clear; we want to grow our visitor economy and the best way to do this is by increasing airline capacity and unlocking new international markets for NSW. We've set our sights on increasing the state's aviation capacity by 8.5 million seats, and this new Hong Kong route will complement other new routes we're securing as we work towards landing this goal." Mr Wang Yu, Consul General of People's Republic of China (Sydney), said: "As the second Hong Kong-based airline to operate the Hong Kong–Sydney route, Hong Kong Airlines not only provides a convenient new option for traveling between China and Australia, but also contributes to enhanced exchanges among students, tourists, business professionals and friends from all walks of life. This new service will strengthen Hong Kong and Sydney's role as vital gateways for the flow of people and goods, injecting fresh momentum into the economic and cultural ties between China and Australia. Its launch will also attract more international travelers to transit through Hong Kong or Sydney, further strengthening both cities' positions as global aviation hubs and creating new opportunities for trade and investment. Looking ahead, the Consulate-General of China in Sydney will continue to encourage and support airlines from both China and Australia in restoring or launching new routes based on the principle of mutual benefit and win-win cooperation. We believe that Hong Kong Airlines will continuously enhance its service quality and showcase a good corporate image." Also in attendance at the Sydney welcome ceremony were representatives from the Consulate-General of the People's Republic of China in Sydney, Destination NSW and the Hong Kong Economic and Trade Office (Sydney). Exclusive Lounge Access for Connecting Passengers To celebrate the launch of the new service, passengers travelling on this route and transit at Hong Kong for selected Hong Kong Airlines flights* to Vancouver, Bali, Tokyo, Osaka, Fukuoka, Shanghai (Pudong), Haikou, or Sanya, between 20 June and 31 October 2025, will receive complimentary access to the airline's flagship lounge "Club Autus" at Hong Kong International Airport. *Please click here for the relevant terms and conditions. Expanding Route Network The launch of the Sydney service indicates Hong Kong Airlines' overarching strategy for its network expansion. Coupled with the various significant destinations that have been inaugurated or reinstated since the start of the year, including Gold Coast in Australia, Vancouver in Canada, and Hulunbuir in Inner Mongolia of mainland China, the airline has cultivated a more extensive and diversified route map. This further underscores Hong Kong Airlines' commitment and contribution to the aviation industry's recovery and long-term development. In addition to the new routes, the Company also increased the frequency of services on multiple routes to cater to the summer travel demand. This includes the resumption of seasonal flights to the Maldives and an increase in flights to Da Nang to two per day. Additionally, flights to Shanghai Pudong will be increased to four per day, while services to Hangzhou and Nanjing will become twice day. The variety of flight times available throughout the day provides business, leisure, and transit passengers with the flexibility to plan their itineraries. The Company will launch another new service in July, providing passengers with more travel options. Hong Kong Airlines flight schedule* between Hong Kong and Sydney is as follows (All times local): Route Flight Number Departure Arrival Frequency HKG – SYD HX017 22:25 09:50+1 Daily SYD – HKG HX018 11:30 19:10 * Flight number and schedule may change without prior notice Please download high-resolution photos through this link. About Hong Kong Airlines Established in 2006, Hong Kong Airlines is a full-service airline firmly rooted in Hong Kong. The airline flies to over 30 destinations across the Asia Pacific and North America, and currently maintains interline and codeshares with multiple airline partners and ferry service providers. Hong Kong Airlines operates an all-Airbus fleet. It has been awarded the internationally acclaimed four-star rating from Skytrax since 2011. For more information, please visit or our social media channels on LinkedIn, Twitter, Instagram and Facebook. View original content to download multimedia: SOURCE Hong Kong Airlines Inicia sesión para acceder a tu portafolio
